Drug Trial Radar · NCT04478734
Trial of the Combined Use of Thiamine and Biotin in Patients With Huntington's Disease
Last checked: Nov 20, 2026Latest source record: Feb 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Apr 12, 2023
Primary completion
Jun 30, 2025
Study completion Dec 30, 2025
Sponsor
- Lead sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en SevillaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
- First posted
- Jul 21, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the safety and tolerability of combined oral thiamine with biotin therapy in patients with Huntington´s disease in mild to moderate stages and it is intended to evaluate the biological effect of the treatment in the central nervous system of these patients using as the main biomarker the increase in the level of thiamine monophosphate (TMP) in cerebrospinal fluid (CSF) of these patients with Huntington Disease (HD) during a follow-up period of one year. Our main hypothesis is that combined thiamine-biotin oral therapy is a secure and well-tolerated treatment, potentially capable of modifying the disease course or avoiding the progression of symptoms in early-stages HD patients
Conditions
- Huntington Disease
Interventions
Moderate doses of Thiamine y BiotinDrug
Thiamine 600 mg every day + Biotin 150mg every day
High doses of Thiamine y BiotinDrug
Thiamine 1200 mg every day + Biotin 300mg every day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events as assessed by clinical examination anamnesis and Analytical monitoring with hematological and biochemical control (hepatic and renal function)Time frame: From signature of informed consent form, at all scheduled visits, to end of follow up week 52
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Hospital Ramón y Cajal
Madrid, Spain · Recruiting
Hospital Universitario de San Sebastián
San Sebastián, San Sebastian, Spain · Recruiting
Virgen del Rocío Hospital
Seville, Seville, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.